Previous 10 | Next 10 |
Start Time: 08:30 End Time: 09:25 Avadel Pharmaceuticals plc (AVDL) Q4 2020 Earnings Conference Call March 09, 2021, 08:30 AM ET Company Participants Greg Divis - CEO Thomas McHugh - CFO Richard Kim - Chief Commercial Officer Jennifer Gudeman - VP of Medical and Clinical Affairs Conference Ca...
Avadel Pharmaceuticals (AVDL): Q4 GAAP EPS of -$0.19 beats by $0.09.Cash, cash equivalents and marketable securities of $221.4MPress Release For further details see: Avadel Pharmaceuticals EPS beats by $0.09
New Drug Application (NDA) for once-nightly FT218 to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy accepted for filing by the FDA; assigned a Prescription Drug User Fee Act (PDUFA) target date of October 15, 2021 Completed key appointments for Comm...
DUBLIN, Ireland, March 04, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy, t...
DUBLIN, Ireland, March 02, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy, t...
The FDA accepts for review Avadel Pharmaceuticals' (AVDL) New Drug Application ((NDA)) for FT218, an once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy.The PDUFA target action date is October 15, 2021. The NDA s...
DUBLIN, Ireland, March 01, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s New Drug Application (NDA) for FT218, an investigational, once-nightly formulation...
DUBLIN, Ireland, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy, announced to...
DUBLIN, Ireland, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy, annou...
Avadel Pharmaceuticals (AVDL) appointed 25-years industry veteran Richard Kim to the newly formed role of Chief Commercial Officer for leading all aspects of the U.S. commercial launch of the company’s lead program, once-nightly FT218, pending regulatory approv...
News, Short Squeeze, Breakout and More Instantly...
Avadel Pharmaceuticals plc Company Name:
AVDL Stock Symbol:
NASDAQ Market:
Avadel Pharmaceuticals plc Website:
DUBLIN, June 27, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it is set to join the broad-market Russell 3000 ® Index at the conclusion of the 2024 Russell US Ind...
2024-05-29 06:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
– 11 accepted abstracts, including new data reiterating satisfaction, preference and clinical benefit of LUMRYZ – – Presentations highlight Avadel’s continued commitment to address gaps in narcolepsy care – DUBLIN, May 22, 2024 (GLOBE NEWSWIRE) -...